Microfluidic Assembly of Liposomes with Tunable Size and Coloading Capabilities


Authors: JR Hoffman, E Tasciotti, R Molinaro

Journal: Multiple Myeloma

DOI: 10.1007/978-1-4939-7865-6_15

Publication - Abstract

May 25, 2018

Small Molecule Drugs Nucleic Acid Lipid Nanoparticles Oncology
Liposomes used for the delivery of pharmaceuticals have difficulties scaling up and reaching clinical translation as they suffer from batch-to-batch variability. Here, we describe a microfluidic approach for creating reproducible, homogenous nanoparticles with tunable characteristics. These nanoparticles of sizes ranging from 30 to 500 nm are rapidly self-assembled by controlling the flow rates of ethanol and aqueous streams. This method of microfluidic assembly allows for the efficient encapsulation of both hydrophobic and hydrophilic drugs in the lipid bilayer and particle core, respectively, either separately or in combination.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Mar 13, 2021
Molecular Therapy Nucleic Acids

Functionalized Lipid Nanoparticles for Subcutaneous Administration of mRNA to Achieve Systemic Exposures of a Therapeutic Protein

N. Davies, D. Hovdal, N. Edmunds, P. Nordberg, S. Andersson, et. al.

mRNA Nucleic Acid Lipid Nanoparticles Other Applications
Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence lo...
Read More


Publication - Abstract

Jan 22, 2021
ACS Nano

Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles

U. Elia, S. Ramishetti, R. Rosenfield, N. Dammes, E. Bar-Haim, G. S. Naidu, E. Makdasi, Y. Yahalom-Ronen, H. Tamir, N. Paran, O. Cohen and D. Peer

mRNA Nucleic Acid Lipid Nanoparticles Vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of vario...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up